Grifols US

Companies 22nd December 2025

FDA approves launch of Grifols fibrinogen for patients with congenital deficiency

Renta 4 | The company has announced FDA approval for the launch in the US of the new fibrinogen concentrate FESILTY for adult and paediatric patients with congenital fibrinogen deficiency. FESILTY is a product developed by Biotest, which will be marketed in the US by Grifols. The company expects FESILTY to be available to US patients experiencing acute bleeding episodes caused by this protein deficiency from the first half of…

Companies 19th November 2025

FDA approves expansion of Grifols’ Thrombate III indication to include paediatric patients

Link Securities | Grifols (GRF) announced that the US Food and Drug Administration (FDA) has approved the expansion of the indication for Thrombate III, the company’s antithrombin III concentrate, to include paediatric patients diagnosed with hereditary antithrombin deficiency (HAD), according to Bolsamanía. With this expansion, Thrombate III becomes the first and only antithrombin concentrate approved for adults and paediatric patients with HAD, an often underdiagnosed blood clotting disorder that could…

Companies, Relevant News Item 17th October 2025

Grifols boosts diagnostics business with €43 million expansion of San Diego plant

Renta 4 | The company has expanded its San Diego (US) campus dedicated to diagnostics and, in particular, blood typing. The expansion, at an approximate cost of $50 million (€43 million), has included the construction of a new plant that nearly doubles the surface area to 18,200 m2. Grifols has begun production of DG Gel cards, used in blood typing tests, and red blood cell reagents, used to detect antibodies….

Relevant News Item 3rd April 2025

Grifols to make €350-million takeover bid for Biotest capital it does not yet control, with aim of delisting it

Bankinter | The company’s Board of Directors has unanimously approved that its subsidiary Grifols Biotest Holdings make a public takeover bid to delist Biotest AG from the stock exchange. The bid will be for the 2.9% of the ordinary shares it does not control and 53.8% of the preference shares. It will offer €43.00 for each ordinary share and €30.00 for each preference share. In addition, it will request the…

Companies, Ibex 25th October 2022

The possible claim Grifols is facing (54-274 €M) does not affect its credit history

Santander | Grifols could be facing a possible claim of 54-274 million euros, according to the newspaper El Economista. On Friday, it emerged that the Spanish blood plasma manufacturer would be facing a class action on the part of 54.000 donors in the state of Illinois, in the United States. The plaintiffs are arguing that Grifols has not complied with the state’s Biometric Privacy Law, since they have demanded that donors…

Companies, Ibex, World economy 22nd October 2022

Grifols Facing A Class Action In The US Related To The Biometric Privacy Law

Renta 4 | Grifols would be facing a class action on the part of 54.000 donors in the state of Illinois, in the United States. The plaintiffs are arguing that Grifols has not complied with the state’s Biometric Privacy Law, since they have demanded that donors provide their fingerprints, not destroy this information and exceed the specific objective for which it was registered. According to the plaintiffs this violated their…

Spanish economy 1st July 2021

Singapore’s Sovereign Wealth Fund Takes 1/3 Stake In Grifols’ US Subsidiary For $1 Billion

Grifols will use all the funds from the sale of Biomat to repay debt, approximately 14% of the €6.2 billion of net financial debt at the end of March, for a leverage level of 5.1 x EBITDA. Although it is not known what percentage of Biomat has been sold, some market sources put it at between 30% and 35%.

Ibex, Markets, Spanish economy 1st March 2021

Grifols Acquires 25 Plasma Donation Centers In The US For $370 M

Grifols now operates 344 plasma centers worldwide: 289 in the U.S. and 55 in Europe across Germany, Austria and, recently Hungary. The 25 centers acquired from BPL are authorized by the U.S. Food and Drug Administration (FDA) and the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA).

Ibex, Markets 26th March 2020

Grifols reaches agreement in the US to seek anti-Covid19 therapy

After announcing that the United States considered it “basic infrastructure” in the coronavirus health emergency, Grifols has signed a multilateral collaboration agreement in that country with the U.S. Advanced Biomedical Research and Development Authority (BARDA), the U.S. Food and Drug Administration (FDA) and other federal public health agencies. The objective will be to collect plasma from patients who have recovered from Covid-19, process it and produce hyperimmune immunoglobulins.

Ibex, Markets 24th March 2020

Trump Declares Grifols’ Centres To Be Essential Infrastructures

US President Donald Trump has reportedly declared Grifols’ donation centers and fractionation plants to be essential infrastructures. So their activity would be guaranteed in the face of a possible economic slowdown. The US is the country where Grifols has most of its fractionation plants and plasma donation centers (more than 92% of the 300 centers it operates).